| 摘要: |
| 目的:观察固本防哮饮辅助沙美特罗替卡松(舒利迭)对哮喘缓解期肺脾气虚证患儿肺功能及气道炎症的影响,为固本
防哮饮的临床应用提供参考。方法:选取我院2023 年9 月-2024 年11 月收治的哮喘缓解期肺脾气虚证患儿80 例,采用随机数
表法分为对照组和观察组各40 例。对照组给予沙美特罗替卡松治疗,观察组给予固本防哮饮联合沙美特罗替卡松治疗。统计
两组哮喘控制效果,评估两组中医症状评分变化,检测并比较两组免疫球蛋白E(IgE)、白细胞介素-6(IL-6)、磷脂酰肌醇3-激
酶/ 蛋白激酶B(P13K/ AKT)通路、IL-8、肿瘤坏死因子-α(TNF-α)及肺功能。结果:观察组哮喘控制效果优于对照组(P<0. 05)。
两组治疗前中医症状评分、肺功能比较差异均无统计学意义(P>0. 05)。治疗后,两组呼气峰值流速(PEF)日变异率、中医症状
评分均降低,且观察组低于对照组(P<0. 05);两组第一秒用力呼气量(FEV1)、FEV1/ 用力肺活量(FVC) 均升高,且观察组高于
对照组(P<0. 05)。两组治疗前P13K/ AKT 通路相关因子相对表达量及IgE、IL-6、IL-8、TNF-α 比较差异均无统计学意义( P>
0. 05)。治疗前后,两组P13K 与AKT1 相对表达量及IgE、IL-6、IL-8、TNF-α 均降低,且观察组低于对照组(P<0. 05)。两组不良
反应比较差异无统计学意义(P>0. 05)。结论:固本防哮饮联合沙美特罗替卡松可改善哮喘缓解期肺脾气虚证患儿肺功能,减
轻症状,可能与调节P13K/ AKT 通路有关。 |
| 关键词: 固本防哮饮 沙美特罗替卡松 哮喘 缓解期 肺脾气虚证 肺功能 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2025.06.004 |
|
| 基金项目:宿迁市中医药科技项目,编号HD202206。 |
|
| Clinical Research on Guben Fangxiao Decoction in the Adjuvant Treatment of Children with Lung and Spleen Qi Deficiency Syndrome in Remission Stage of Asthma |
| Wu Jianxin, Ge Kai,Lin Jingxia, Sun Jie |
| (Shuyang County Traditional Chinese Medicine Hospital, Jiangsu Suqian 223600,China) |
| Abstract: |
| Objective: To observe the effects of salmeterol ticarcoson (Seretide) combined with Guben Fangxiao decoction on lung
function and airway inflammation in children with lung and spleen Qi deficiency syndrome in remission stage of asthma, and to provide
reference for the clinical application of Guben Fangxiao decoction. Methods: Eighty children with lung and spleen Qi deficiency
syndrome in remission stage of asthma admitted into our hospital from Sept. 2023 to Nov. 2024 were selected to be divided into the
control group and observation group by the random number table method, with 40 cases in each group. The control group was treated
with salmeterol ticarcoson, while the observation group received Guben Fangxiao decoction combined with salmeterol ticarcoson. The
asthma control effect of two groups was counted, changes in traditional Chinese medicine symptom scores of two groups were assessed,
and differences in immunoglobulin E (IgE), interleukin-6 (IL-6), phosphatidylinositol 3-kinase/ protein kinase B (P13K/ AKT)
pathway, IL-8, tumour necrosis factor-α (TNF-α), and lung function were detected in two groups. Results: The asthma control effect
of observation group was better than that of control group (P<0. 05). There was no statistically significant difference in the scores of
traditional Chinese medicine symptom and lung function between two groups before treatment (P >0. 05). After treatment, the daily
variation rate of peak expiratory flow (PEF) rate and traditional Chinese medicine symptom score in both groups decreased, and the
observation group was lower than control group (P<0. 05). The forced expiratory volume at one second (FEV1) and FEV1/ forced vital
capacity (FVC) in both groups increased, and the observation group was higher than control group ( P < 0. 05). There was no
statistically significant difference in the relative expression of factors related to P13K/ AKT pathway, IgE, IL-6, IL-8, and TNF-α
between two groups before treatment (P>0. 05). Before and after treatment, the relative expression of P13K and AKT1, IgE, IL-6, IL-8
and TNF-α in both groups decreased, and the observation group was lower than the control group (P<0. 05). There was no statistically
significant difference in adverse drug reactions between two groups (P>0. 05). Conclusion: Guben Fangxiao decoction combined with
salmeterol ticarcoson can improve the lung function of children with lung and spleen Qi deficiency syndrome in remission stage of asthma,
which may be related to the regulation of P13K/ AKT pathway. |
| Key words: Guben Fangxiao decoction salmeterol ticarcoson asthma remission lung and spleen Qi deficiency syndrome lung function |
